
Roche Diagnostics (F. Hoffmann-La Roche AG division)
Roche Diagnostics
Roche Diagnostics is the diagnostics division of F. Hoffmann-La Roche AG, the world's largest in-vitro diagnostics (IVD) company, headquartered in Rotkreuz, Switzerland. The division was formally established in 1968 and generated CHF 13.8 billion in FY2025 sales, serving clinical laboratories, hospitals, and point-of-care settings in 150+ countries. Roche Diagnostics holds the #1 global market share in IVD across immunoassay, clinical chemistry, molecular diagnostics, and tissue pathology, with its cobas family of analyzers running billions of tests annually. The division's closed-system model — proprietary instruments paired with high-margin consumables and reagents — creates one of the most defensible recurring-revenue engines in medical technology.
Strengths: Roche Diagnostics commands the world's broadest immunodiagnostics test menu, spanning oncology, cardiology, infectious disease, and endocrinology. The cobas integrated laboratory platform delivers unmatched automation for high-volume labs, while the molecular diagnostics franchise (PCR, viral load, MRD) leads the market in infectious disease and oncology monitoring. The division's companion diagnostics partnership model — co-developing tests with pharmaceutical partners — locks in long-term clinical adoption. Pathology sales surged 14% to CHF 1.7 billion in FY2025, fueled by the Ventana tissue-imaging franchise and the $1.05 billion PathAI acquisition. The division also leads in molecular residual disease monitoring through Foundation Medicine and the $595 million SAGA Diagnostics acquisition.
Weaknesses: Roche Diagnostics' closed-system strategy faces pricing pressure in emerging markets, particularly China, where government procurement reforms and VBP tenders have eroded instrument attachment rates. The division's high dependence on consumable pull-through makes it vulnerable when laboratory volumes stagnate. Regulatory scrutiny of data exclusivity and interoperability continues to challenge the closed-ecosystem model in Europe and the United States.Read MoreShow Less
Strengths: Roche Diagnostics commands the world's broadest immunodiagnostics test menu, spanning oncology, cardiology, infectious disease, and endocrinology. The cobas integrated laboratory platform delivers unmatched automation for high-volume labs, while the molecular diagnostics franchise (PCR, viral load, MRD) leads the market in infectious disease and oncology monitoring. The division's companion diagnostics partnership model — co-developing tests with pharmaceutical partners — locks in long-term clinical adoption. Pathology sales surged 14% to CHF 1.7 billion in FY2025, fueled by the Ventana tissue-imaging franchise and the $1.05 billion PathAI acquisition. The division also leads in molecular residual disease monitoring through Foundation Medicine and the $595 million SAGA Diagnostics acquisition.
Weaknesses: Roche Diagnostics' closed-system strategy faces pricing pressure in emerging markets, particularly China, where government procurement reforms and VBP tenders have eroded instrument attachment rates. The division's high dependence on consumable pull-through makes it vulnerable when laboratory volumes stagnate. Regulatory scrutiny of data exclusivity and interoperability continues to challenge the closed-ecosystem model in Europe and the United States.
Listed market data
ROG · SIX · weeklyHistory →- Market cap
- $2.6 B
- Share price
- CHF 119.83
- 1Y change
- +54.6%
- Recent change
- -2.1%
- Since first close
- ×24.1
- Revenue (TTM)
- CHF$13.8 B (FY2025)
11-18 → 11-19
from 1980-03
Financial history
Full market history- 2026-11CHF 119.83$2.6 B-9.9%
- 2026-10CHF 133.06$2.9 B-13.0%
- 2026-09CHF 152.99$3.4 B+21.8%
- 2026-08CHF 125.57$2.8 B+1.7%
- 2026-07CHF 123.47$2.7 B-24.6%
- 2026-06CHF 163.73$3.6 B+15.7%
- 2026-05CHF 141.52$3.1 B+4.3%
- 2026-04CHF 135.75$3 B+26.5%
- 2026-03CHF 107.33$2.4 B-0.5%
- 2026-02CHF 107.83$2.4 B+10.9%
- 2026-01CHF 97.24$2.1 B+6.2%
- 2025-12CHF 91.57$2 B—
Ownership & Control
Shareholding as of 2026-06-30- Controlling entity
- Publicly held — no controlling shareholder disclosed
- Company type
- Brand & Manufacturer
- Insiders
- 1.22%
- Institutions
- 103.14%(428 holders)
- Free float
- 98.78%
Percentages are of total shares outstanding, aggregated from 13F-style filings via Yahoo Finance. Institutional figures reflect US-filed positions and may undercount owners filing elsewhere. No figure is shown where none is disclosed.
In the press
All coverage →5 latest headlines1- Lilly and Roche Diagnostics expand early Alzheimer’s blood testing in Korea - CHOSUNBIZ - Chosunbizbiz.chosun.com2026-10-19
- Reminder: Invitation to Roche's 3rd Quarter Sales 2026 Presentation - Rochewww.roche.com2026-10-15
- Roche Diagnostics delivers laboratory equipment to support Ebola testing in DRC - PR Newswirewww.prnewswire.com2026-10-07
- Roche Taps Foundation Medicine Chief to Lead North American Diagnostics Business - The Healthcare Technology Report.thehealthcaretechnologyreport.com2026-08-20
- ChemoMetec enters collaboration agreement with Roche Diagnostics - Yahoo Financefinance.yahoo.com2026-08-10
• cobas e-series immunoassay analyzers
• Elecsys test menu oncology, cardiology, thyroid, infectious disease
Clinical Chemistry & Lab Automation – Core Business
• cobas c-series chemistry analyzers
• Integrated pre-analytics and laboratory automation
Molecular Diagnostics – Core Business
• cobas PCR and viral load monitoring systems
• MRD molecular residual disease platforms Foundation Medicine, SAGA
• Infectious disease molecular panels
Tissue Pathology – Core Business
• Ventana slide staining platforms
• Digital pathology and AI image analysis PathAI
Point-of-Care & Diabetes Care – Core Business
• cobas b blood gas analyzers
• Blood glucose monitoring systems
Quick Facts
Headquarters
Founded
Employees
Revenue
Market cap
Factories
Presence
Categories
17 categories · scroll for more
Related
Similar listed companies
- Eli Lilly and Company· $1.3 T
- Johnson & Johnson (J&J)· $653 B
- ASML Holding N.V.· $598 B
- Allergan Aesthetics· $508 B
- AbbVie Inc.· $504 B
- General Electric Company (GE)· $405 B
Data Sources & Methodology
This corporate profile is compiled from publicly available sources including company annual reports, SEC/regulatory filings, official press releases, and verified third-party industry databases. Financial figures reflect the most recent fiscal year disclosures and are cross-validated across multiple independent references.
VerityRank Score is calculated using a proprietary multi-dimensional model evaluating market presence, financial strength, operational scale, innovation capacity, and brand influence. Individual dimension scores are normalized against industry peers and updated quarterly.
Disclaimer: This profile is for informational purposes only. VerityRank makes no warranties regarding completeness or timeliness. This content does not constitute investment advice or endorsement.
Key references: Official Website SIX: ROG (parent F. Hoffmann-La Roche AG) , Roche to Acquire PathAI — Official Press Release
Roche Diagnostics FY2025 Analysis — Fierce Biotech
Roche Diagnostics Global Locations
Roche Foundation Medicine SAGA Diagnostics MRD Platform Update
